THE HAGUE, The Netherlands--(BUSINESS WIRE)--Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas. This technology enables - for the first time - targeted killing of only the unwanted bacteria, regardless of resistance.
ZUG, Switzerland--(BUSINESS WIRE)--Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer. Their significant leadership experience within large, global pharmaceutical organisations will enable Micreos to accelerate the journey of developing viable alternatives to traditional antibiotics in select medical indications by leveraging proprietary endolysin technology, which selectively targets and kills harmful bacteria while preserving the rest of the microbiome.
THE HAGUE, Netherlands, Oct. 14, 2021 /PRNewswire/ -- Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland. Following rapid growth, Micreos is preparing to spin-out its Pharmaceutical business into a separate company as per January 2022 to directly access the capital markets. This will help to fund pipeline development to progress its highly innovative, targeted antibacterial technology platform into pharmaceutical solutions that can improve patient care.
Investors have bought into Micreos’ vision for a sustainable alternative to antibiotics. With backers putting up 32 million euros ($37 million), Micreos is now poised to show whether its platform can generate more targeted, harder-to-resist ways of taking out bacteria.
BEDFORD, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the pheEDIT Phase 1 clinical trial for HMI-103, a one-time, in vivo product candidate that utilizes a gene editing approach for phenylketonuria (PKU), based on the Investigational New Drug Application (IND) clearance from the U.S. Food and Drug Administration (FDA). HMI-103 will be the world’s first gene editing candidate for PKU to enter clinical trials from Homology’s dual gene therapy and gene editing technology platform, and with the launch of pheEDIT Homology moves closer to its goal of offering solutions for both adults and pediatric patients with PKU.